The ability of 3-hydroxypyridin-4-ones (CP), a family of bidentate orally effective iron chelators, to remove iron and to prevent iron-induced lipid peroxidation was studied in beating rat myocardial cells in culture. The iron (111) binding constant (log p3) of all CP compounds is 36, but their lipophilicity may be modified by altering the length of the R2 substituent on the ring nitrogen. There was a direct relation between lipid solubility and chelating efficiency. Although at high concentrations all CP compounds were more effective in iron mobilization than deferoxamine, the opposite was true for low concentrations. Further studies with 1.2-diethyl-3-hydroxypyridin-4-one (CP94). the most effective CP com-RANSFUSIONAL SIDEROSIS is one of the most T important life-limiting complications of thalassemia major. Although deferoxamine (DF) treatment is able to induce a negative iron balance and prolong life by preventing the accumulation of iron in vital organs, such treatment is far from satisfactory. The high cost of DF, its limited oral effectiveness, and the consequent need for its parenteral administration by cumbersome and expensive portable pumps, underline the need for the development of new, orally effective inexpensive iron-chelating drugs.'
lipophilicity may be modified by altering the length of the R2 substituent on the ring nitrogen. There was a direct relation between lipid solubility and chelating efficiency. Although at high concentrations all CP compounds were more effective in iron mobilization than deferoxamine, the opposite was true for low concentrations. Further studies with 1.2-diethyl-3-hydroxypyridin-4-one (CP94). the most effective CP com-RANSFUSIONAL SIDEROSIS is one of the most T important life-limiting complications of thalassemia major. Although deferoxamine (DF) treatment is able to induce a negative iron balance and prolong life by preventing the accumulation of iron in vital organs, such treatment is far from satisfactory. The high cost of DF, its limited oral effectiveness, and the consequent need for its parenteral administration by cumbersome and expensive portable pumps, underline the need for the development of new, orally effective inexpensive iron-chelating drugs. ' The 3-hydroxypyridin-4-ones (CP compounds) are a family of bidentate orally effective iron chelators designed by Hider and Kontoghiorghes as potentially useful drugs for the management of clinical iron ~v e r l o a d .~-~ These compounds have been shown to be effective iron chelators in vitro in hepatocyte cultures6 and in vivo in a number of animal species?' One of these compounds, 1,2-dimethyl-3-hydroxypyridin-4-one (L1 or CP 20) has already been tested in a limited number of patients with transfusional iron overload, and was found to have comparable oral efficiency to subcutaneous DF in promoting urinary iron excretion?."
Because the most critical manifestation of iron overload is damage to the heart, we have developed an experimental model of rat myocardial cells in culture for studying the harmful effects of iron and the protective effects of iron chelati~n.'~-'~ A unique feature of these cultures is their ability to differentiate into spontaneously contracting cells, providing an opportunity to study simultaneously the biochemical and functional effects of iron toxicity in heart cells. In the present studies we have used this iron-loaded heart cell culture model to study the ability of the CP compounds to remove iron directly from myocardial cells, to compare their efficiency with that of DF for removing iron and inhibiting lipid peroxidation, and to define optimal conditions for their iron-chelating activity.
MATERIALS AND METHODS
Ham F-10 culture medium supplemented with CaC1,. H,O 135 m a , penicillin 200,000 U/L, streptomycin 0.2 mgL, 10% horse serum, and 10% fetal bovine serum (Beth Ha'Emek, Israel) was used as growth medium. For iron-loading experiments, heterologous serum was replaced by serum-free medium. For mincing and washing the organs and for trypsinization, H solution (Ham F-10 pound, have shown that iron mobilization is completed within 6 hours, that effective mobilization requires a drug: iron molar ratio exceeding 3:l permitting the formation of a hexadentate complex, and that the beneficial effects of iron mobilization are manifested in a marked reduction in membrane lipid peroxidation as indicated by cellular malonaldehyde content. Our study represents the first demonstration of a direct interaction between myocardial cells and an orally effective iron chelator, and underlines the need for high molar concentrations for achieving an optimal therapeutic effect. The N-alkyl-3-hydroxypyridin-4-one chelators (CP compounds) were synthesized and purified as previously described' and their purity was confirmed by 'H nuclear magnetic resonance, reversephase high performance liquid chromatography, and elemental analysis. D F B was supplied as the methane-sulfonate salt (Desferal) by Ciba-Geigy Ltd (Basel, Switzerland). The chemical structure and partition coefficients of the CP compounds used in the present study are described in Table 1 .
Cultures from 1-day-old rats (Hebrew University strain) were obtained by methods described in detail in our previous studie~.''-'~~'' Briefly, the ventricles were minced and trypsinized, and the combined fractions resuspended in growth medium into a sterile 250-mL flask (Nunc; Nunclon Delta, Herlev, Denmark) through a sterile mesh to exclude explants. The pooled cells were diluted in growth medium to a density of 9 X lo5 to 1 X lo6 cells/mL and seeded into a 35-mm diameter Petri dish (Falcon 3001; Falcon Labware, Oxnard, CA). After 24 to 36 hours this 
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concentration yielded an almost confluent layer of beating heart cells at a final density of about 2 x 106 cells. Cultures were kept at 37°C in an atmosphere of 5% CO, and 95% air. Experiments were performed at 5 days of culture when over 80% of the cells were beating myocardial cells. Continued viability of cultured ironloaded cells was documented by supravital dye exclusion and by the absence of enzyme (lactate dehydrogenase) leakage into the culture medium after 24-hour iron loading. 59FeC1, (specific activity 10 to 15 kCi/kg; Amersham Radiochemical Centre, Amersham, England) was diluted in 0.005N HCI and mixed with sufficient sterile ferric ammonium citrate (BDH Fine Chemicals Ltd, Poole, England) to provide a concentration of 100 kg/mL of elemental iron. In most studies, unless otherwise stated, a final concentration of 20 &mL of iron was used for iron loading and radioiron labeling of heart cell cultures. At the termination of studies, culture plates were washed twice with 1 mL of cold culture medium. The cells were scraped and transferred into counting tubes by means of a rubber policeman and resuspended in 0.5 mL of culture medium. 5' %e activitywas determined in an automatic well scintillation counter (Auto-Gamma model 5360 Packard Instrument Co, Inc, Downers Grove, IL),
Radioactive iron labeling.
RESULTS
The ability of the various CP compounds to remove 59Fe from iron-loaded heart cells is described in Table 2 . Heart cell cultures were preincubated with j9Fe-labeled ferric ammonium citrate at a concentration of 20 Fg/mL iron (3.6 mmol/L) for 24 hours. Subsequently, the iron-rich medium was replaced by normal culture medium, and various CP compounds were added at 0.1 and 1.0 mmol/L concentrations for an additional 24 hours. Residual radioactivity was expressed either as the percent of 59Fe added to the cultures during iron loading, or as the percent of radioactivity in untreated control cultures. As shown in Table 2 , at the lower molar concentration DF was able t o reduce the iron content of iron-loaded heart cells by more than 52%, whereas at the same molar concentration all CP compounds were considerably less active with iron mobilization ranging from 9% to 16%. In contrast, at the higher concentration tested all CP compounds were as effective or better than DF, with 87% to 89% of the cellular iron deposits being removed within 24 hours.
In view of its superior chelating efficiency in the present as well as previous experiments, compound CP94 has been selected for more detailed studies. The effect of incubation duration on iron mobilization and on cellular MDA content is described in Table 3 . With both D F and CP94 used at a concentration of 1.0 mmol/L, a rapid early mobilization of cellular iron has been observed reaching a plateau after about 6 hours. At all times studied, CP94 was slightly but significantly more effective than DF. Iron mobilization with both compounds was accompanied by a reduction in cellular MDA content. However, this was not directly proportional to the amount of iron removed. Despite removal of 30% to 40% of cellular iron within the first hour of iron chelation, no MDA reduction was observed with either compound until 3 hours of treatment. In addition, in cultures treated by CP94, reduction in MDA was less pronounced than with DF, despite a greater efficiency of iron removal.
The effect of drug concentration on chelating efficiency is described in Table 4 . In contrast to concentrations of 0.1 and 0.25 mmol/L in which DF was clearly more effective than CP94, the opposite was true for drug concentrations of 0.75 and 1.0 mmol/L. However, there were only minor differences in MDA concentrations, with CP94 being slightly less effective at most concentrations studied. In all of the previously described studies a constant iron concentration of 0.36 mmol/L has been used for iron loading of cultured heart cells before chelation treatment. The reduced chelating efficiency of CP94 at 0.1 and 0.25 mmol/L and its marked enhancement at 0.75 and 1.0 mmol/L suggested that the chelating effect of CP94 may depend on the ratio of molar concentrations of iron to drug. A study designed to investigate this possibility is presented in Table 5 . An intermediate concentration of 0.25 mmol/L was used for both D F and CP94. In contrast, iron concentrations used for iron loading before chelating treatment ranged from 5 (0.09 mmol/L) to 80 (1.43 mmol/L) pg/mL. The first column (Control) in Table 5 describes the effect of iron concentrations on cellular iron uptake. With increasing iron concentrations there was a gradual reduction in the proportion of iron deposited in cultured cells ranging from 21% at the lowest to 7% at the highest iron concentrations used. D F had an excellent effect on iron mobilization at all concentrations used and, quite unexpectedly, the most striking effect (93% iron removed) was found at the highest iron concentrations. The relation of CP94 effect to iron concentrations was quite different. At 5 pg/mL of iron, CP94 was significantly more effective than DF. In contrast, at 80 pg/mL the effect of CP94 was reduced to about one half that of DF. The chelating efficiency (millimole of iron removed per millimole of chelator added) of DF and CP94 was 5.9% and 6.4%, respectively, at 5 pg/mL iron, and 39.4% and 22.1%, respectively, at 80 pg/mL iron.
DISCUSSION
Cardiac disease represents the leading cause of mortality in transfusional hemosiderosis. Once clinical heart disease is established, most patients die within less than 1 year.'* However, with the establishment of regular iron-chelating therapy, a significant improvement in life expectancy has been witnessed. This is attributed mainly to the prevention of heart disease in well-treated patients and, in a few, to the reversal of existing heart disease by aggressive intravenous DF therapy.''-*'
One of the important objectives in the evaluation of new iron-chelating compounds designed for clinical use is demonstration of their ability to interact directly with iron accumulated within heart cells. Accordingly, we have used our heart cell model to investigate the iron-chelating properties of the CPs, a family of bidentate orally effective iron chelators with an identical, and very high (log p, 36) binding constant and selective affinity to Fe (111). Comparison of the amounts of iron mobilized from iron-loaded heart cells by the various CP compounds has shown that, similar to previous experience in liver cell cultures, there was a direct relation between lipid solubility and chelating efficiency, and that the least and most efficient compounds (CP40 and CP94, respectively) were also the least (CP40) and most (CP94) lipid soluble. In view of the superior For scavenging efficiency of CP94 in the present in vitro study as well as in our previous in vivo ~tudies,'~ we have focused all subsequent experiments on this compound.
Comparison of the rates of iron mobilization by DF and CP94 at a concentration of 1 mmol/L indicated a clear advantage for CP94 throughout the 24-hour period of study. This advantage is even more impressive when considering the need for a 3:l drughron molar ratio to form a hexadentate complex with CP94 versus a 1:1 ratio for DF, and is probably explained by the very high stability constant with iron of the hydroxypyridin-Cone compo~nds.~ However, this advantage in iron mobilization did not manifest itself in a more effective inhibition of iron-induced lipid peroxidation, as reflected in cellular MDA concentrations.
Previous studies of dose-response relations with DF in iron-loaded heart cells have shown a direct relation between extracellular DF concentrations and iron mobilization.12 A similar study of CP94 has shown an unexpected difference in its efficiency at high and low drug concentrations compared with DF. Whereas at 1 mmol/L CP94 was clearly more effective than DF, the opposite was true for 0.1 and 0.25 mmol/L concentrations. Because a concentration of 0.36 mmol/L iron was used for iron loading in all of these studies and because improved efficiency of CP94 could be shown at drug concentrations of 0.5 mmol/L and above, these findings implied that optimal chelating efficiency of CP94 requires drug concentrations exceeding a 1:l drug/ iron ratio. Support for this concept is provided by the observation that with a constant drug concentration of 0.25 mmol/L, CP94 was more effective than DF at low iron concentrations, whereas at high iron concentrations the effect of DF exceeded by far that of CP94. However, the above figures relate to extracellular concentrations of iron and chelator, and the actual concentrations of intracellular chelatable iron in the washed iron-loaded cells and of the drugs studied are unknown.
In an attempt to explain the difference between the predictable dose-related effect of DF and the anomalous behavior of the CP compounds, one should remember that DF is a hexadentate chelator whereas the CP compounds are bidentate chelators. Each molecule of DF combines with one atom of Fe (111), producing a kinetically inert, water-soluble complex that is extremely effective in preventing iron-dependent hydroxyl radical formation.Z5s26 In contrast, bidentate chelators, such as the CP compounds, are able to form three types of iron complexes: do not generate free hydroxyl radicals.'' However, it is possible that at suboptimal concentrations of the CP compounds, or in the presence of a large excess of iron, a substantial proportion of the chelated iron will exist as the polar complexes [Fe-LIZ+ and [Fe-L,]' which, in a similar fashion to iron-EDTA chelates, may promote hydroxyl radical formation by altering the redox potential of the metaLz5 Such intermediate compounds may also be less effective in promoting the excretion of chelated iron from within the cell. We propose that the relatively low efficiency of the CP compounds at low molar concentrations or in the presence of excess iron may be explained by their reduced ability to form neutral 3:l complexes with the Fe (111) available for chelation.
A number of clinical studies are presently under way to determine the efficiency of oral treatment by L1 (CP20) in patients with transfusional iron overload. Results of these trials and those to be conducted in the future with some of the most promising CP compounds will provide critical information regarding the suitability of these compounds for clinical use. Results of in vitro studies, such as the present one, should not be directly extrapolated to the clinical setting without reservations. Nevertheless, our data raise important issues to be examined in future clinical trials by: (1) showing that the CP compounds are able to remove iron directly from the iron-loaded heart; (2) emphasizing the need for using high doses for obtaining optimal drug efficiency; and (3) underlining the possible risk of a paradoxical effect with low-dose therapy. The last point is particularly important in view of recent pharmacokinetic data in humans indicating that maximal plasma concentrations after oral treatment with L1 may not exceed 0.13 mmol/L.28 2118176, 1982 chelating drugs. Clin Haematol2: 257, 1989 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
